Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Neutropenia 3Breast Neoplasms 2

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × eflapegrastim × Clear all
NCT01724866 2022-04-15

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
148 enrolled 45 charts

Neutropenia

NCT02643420 2022-03-02

ADVANCE

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
406 enrolled 19 charts
Breast

Breast Neoplasms, Neutropenia

NCT02953340 2022-03-02

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
237 enrolled 18 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡